翰宇药业
(300199)
| 流通市值：110.18亿 | | | 总市值：137.79亿 |
| 流通股本：7.06亿 | | | 总股本：8.83亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 375,225,390.5 | 255,720,574.14 | 150,256,744.79 | 431,384,112.87 |
| 营业收入 | 375,225,390.5 | 255,720,574.14 | 150,256,744.79 | 431,384,112.87 |
| 二、营业总成本 | 459,578,775.38 | 309,314,966.43 | 156,147,173.76 | 888,444,319.54 |
| 营业成本 | 151,708,440.89 | 102,068,191.24 | 59,400,451.09 | 218,686,716.09 |
| 税金及附加 | 6,045,567.47 | 4,537,164.55 | 1,447,681.36 | 12,656,249.32 |
| 销售费用 | 70,260,228.9 | 43,338,190.83 | 16,088,786.79 | 242,641,567.93 |
| 管理费用 | 85,209,042.23 | 60,577,268.49 | 29,821,195.75 | 127,699,778.62 |
| 研发费用 | 59,329,000.15 | 40,911,586.37 | 18,999,351.04 | 161,495,617.93 |
| 财务费用 | 87,026,495.74 | 57,882,564.95 | 30,389,707.73 | 125,264,389.65 |
| 其中:利息费用 | 79,425,721.27 | 53,147,900.5 | 26,164,132.23 | 120,461,172.45 |
| 其中:利息收入 | 191,207.56 | 131,998.21 | 102,893.91 | 216,652.69 |
| 加:公允价值变动收益 | - | - | - | 44,491,998.06 |
| 加:投资收益 | -529,557.23 | -181,717.39 | - | -9,785,663.14 |
| 资产处置收益 | 42,676,324.14 | 43,009,866.4 | 664,407.59 | -512,286.49 |
| 资产减值损失(新) | 3,465,987.55 | 5,040,472.13 | 62,258.13 | -126,095,488.69 |
| 信用减值损失(新) | -5,424,779.04 | -4,779,460.42 | -3,388,149.62 | -8,854,452.69 |
| 其他收益 | 17,937,162.77 | 7,789,038.81 | 3,637,297.07 | 50,311,442.18 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -26,228,246.69 | -2,716,192.76 | -4,914,615.8 | -507,504,657.44 |
| 加:营业外收入 | 98,331.8 | 20,685.25 | 858.03 | 260,946.9 |
| 减:营业外支出 | 1,464,030.72 | 1,121,853.07 | 4,685,646.27 | 3,859,611.21 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -27,593,945.61 | -3,817,360.58 | -9,599,404.04 | -511,103,321.75 |
| 减:所得税费用 | 8,234,810.62 | 7,154,029.21 | 4,750,646.98 | 4,339,473.43 |
| 六、净利润 | -35,828,756.23 | -10,971,389.79 | -14,350,051.02 | -515,442,795.18 |
| 持续经营净利润 | -35,828,756.23 | -10,971,389.79 | -14,350,051.02 | -515,442,795.18 |
| 归属于母公司股东的净利润 | -34,805,639.91 | -10,358,793.27 | -14,102,003.37 | -513,876,149.69 |
| 少数股东损益 | -1,023,116.32 | -612,596.52 | -248,047.65 | -1,566,645.49 |
| (一)基本每股收益 | -0.04 | -0.01 | -0.02 | -0.58 |
| (二)稀释每股收益 | -0.04 | -0.01 | -0.02 | -0.58 |
| 八、其他综合收益 | -713,914.14 | 644,068.57 | 238,209.62 | 1,771,775.42 |
| 归属于母公司股东的其他综合收益 | -713,914.14 | 644,068.57 | 238,209.62 | 1,771,775.42 |
| 九、综合收益总额 | -36,542,670.37 | -10,327,321.22 | -14,111,841.4 | -513,671,019.76 |
| 归属于母公司股东的综合收益总额 | -35,519,554.05 | -9,714,724.7 | -13,863,793.75 | -512,104,374.27 |
| 归属于少数股东的综合收益总额 | -1,023,116.32 | -612,596.52 | -248,047.65 | -1,566,645.49 |
| 公告日期 | 2024-10-30 | 2024-08-24 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |